Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 911

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5
Chunk 911
---
,000  
    $2,713,000 
  
    Insurance premium financed 
    $-  
    $873,000 
  
    Purchase of property, plant and equipment included in accounts payable and accrued expenses 
    $81,000  
    $299,000 
  
    Right-of-use assets obtained in exchange for new operating lease obligations 
    $3,230,000  
    $- 
  
    Change in extension assumptions of right-of-use assets for operating lease obligations 
    $(557,000) 
    $- 
  
    Reclassification of deferred commitment fees from prepaid expenses into
debt issuance costs 
    $331,000  
    $- 

The accompanying notes are an integral part
of these consolidated financial statements

F-8

HARROW, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Years Ended December 31, 2024 and 2023

NOTE 1. ORGANIZATION

Harrow, Inc. (together with its consolidated subsidiaries,
unless the context indicates or otherwise requires, the “Company” or “Harrow”) is a leading eyecare pharmaceutical
company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market.
Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription
pharmaceutical products accessible and affordable to millions of Americans each year. The Company owns commercial rights to one of the
largest portfolios of branded ophthalmic pharmaceutical products in the U.S. all of which are marketed under its Harrow name. The Company
also owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical-compounding businesses.

The Company owns non-controlling equity interests
in Surface Ophthalmics, Inc. (“Surface”) and Melt Pharmaceuticals, Inc. (“Melt”), both companies that began as
subsidiaries of Harrow. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.

Effective September 29, 2023, the Company changed
its corporate name from Harrow Health, Inc. to Harrow, Inc. pursuant to a Certificate of Amendment to the Company’s Amended and
Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware.

NOTE 2. SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES